Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.42 |
| ▸ | KDM1A | O60341 | 5/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.35 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.35 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.35 |
| ▸ | GPX4 | P36969 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MITF | O75030 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.34 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31166095 | 0.79 | HDAC6 (0.40) | HDAC6MCHR1KCNQ2F2TPSAB1 | |
| SCHEMBL20852601 | 0.79 | PRMT5 (0.41) | HDAC6GAAPKMALOX15HSD17B10 | |
| SCHEMBL17545232 | 0.78 | ESR2 (0.50) | HDAC6RAB9ANPC1KDM4E | |
| SCHEMBL17545235 | 0.74 | MEN1 (0.42) | RAB9ANPC1F2TPSAB1TPSD1 | |
| SCHEMBL30554642 | 0.70 | DAO (0.50) | RAB9ANPC1GAAPKMALOX15 | |
| SCHEMBL6246731 | 0.70 | ALDH1A1 (0.51) | RAB9ANPC1GAAPKMALOX15 | |
| SCHEMBL13739512 | 0.70 | GAA (0.42) | RAB9ANPC1GAAPKMALOX15 | |
| SCHEMBL19609239 | 0.70 | HDAC6 (0.39) | HDAC6KDM1AF2TPSAB1TPSD1 | |
| SCHEMBL22481607 | 0.70 | HSP90AA1 (0.47) | RAB9ANPC1GPX4PKMTSHR | |
| SCHEMBL17552163 | 0.70 | MEN1 (0.40) | HDAC6RAB9AF2TPSAB1TPSD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3186232-B1 | P38 MAP KINASE INHIBITING INDANYL UREA COMPOUNDS | TORRENT PHARMACEUTICALS LTD (IN) | 2019-03-27 | — | — | EP | disclosed |
| EP-3186232-B1 | P38 MAP KINASE INHIBITING INDANYL UREA COMPOUNDS | TORRENT PHARMACEUTICALS LTD (IN) | 2019-03-27 | — | — | EP | disclosed |
| US-9963463-B2 | Urea-substituted indanes as P38 map kinase inhibitors | TORRENT PHARMACEUTICALS LIMITED (IN) | 2018-05-08 | — | — | US | disclosed |
| US-9963463-B2 | Urea-substituted indanes as P38 map kinase inhibitors | TORRENT PHARMACEUTICALS LIMITED (IN) | 2018-05-08 | — | — | US | disclosed |
| US-9963463-B2 | Urea-substituted indanes as P38 map kinase inhibitors | TORRENT PHARMACEUTICALS LIMITED (IN) | 2018-05-08 | — | — | US | disclosed |
| US-20170247390-A1 | P38 MAP KINASE INHIBITING INDANYL UREA COMPOUNDS | TORRENT PHARMACEUTICALS LIMITED (IN) | 2017-08-31 | — | — | US | disclosed |
| US-20170247390-A1 | P38 MAP KINASE INHIBITING INDANYL UREA COMPOUNDS | TORRENT PHARMACEUTICALS LIMITED (IN) | 2017-08-31 | — | — | US | disclosed |
| US-20170247390-A1 | P38 MAP KINASE INHIBITING INDANYL UREA COMPOUNDS | TORRENT PHARMACEUTICALS LIMITED (IN) | 2017-08-31 | — | — | US | disclosed |
| EP-3186232-A1 | P38 MAP KINASE INHIBITING INDANYL UREA COMPOUNDS | Torrent Pharmaceuticals Limited (IN) | 2017-07-05 | — | — | EP | disclosed |
| WO-2016030852-A1 | P38 MAP KINASE INHIBITING INDANYL UREA COMPOUNDS | TORRENT PHARMACEUTICALS LIMITED (IN) | 2016-03-03 | — | — | WO | disclosed |
| WO-2016030852-A1 | P38 MAP KINASE INHIBITING INDANYL UREA COMPOUNDS | TORRENT PHARMACEUTICALS LIMITED (IN) | 2016-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247390-A1 | P38 MAP KINASE INHIBITING INDANYL UREA COMPOUNDS | MAPK1, MAP3K11, MAPK3 | HDAC6 354/4885KDM1A 3920/4885MCHR1 3075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.